Search Results - Allen Lee Cohn

Refine Results
  1. 1
    Impact of a Commercial Reference Laboratory Test Recurrence Score on Decision Making in Early-Stage Breast Cancer

    Impact of a Commercial Reference Laboratory Test Recurrence Score on Decision Making in Early-Stage Breast Cancer by Ruth Oratz, Dev Prosad Paul, Allen Lee Cohn, Scot Sedlacek

    Published 2007
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOX–Bevacizumab or FOLFIRI–Bevacizumab: Results From ARIES, a Bevacizumab Observational Cohort Study

    Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOX–Bevacizumab or FOLFIRI–Bevacizumab: Results From ARIES, a Bevac... by Johanna C. Bendell, Tanios Bekaii‐Saab, Allen Lee Cohn, Herbert I. Hurwitz, M. Kozloff, Haluk Tezcan, Nancy Roach, Yong Mun, Susan Fish, E. Dawn Flick, Darshan Dalal, Axel Grothey

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study

    Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study by Robin Kate Kelley, Chris Verslype, Allen Lee Cohn, T.-S. Yang, Wu‐Chou Su, Howard A. Burris, Fadi Braiteh, Nicholas J. Vogelzang, Alexander I. Spira, Paul Foster, Y. Lee, Eric Van Cutsem

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update

    A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update by Vicky Makker, Carol Aghajanian, Allen Lee Cohn, Margarita Romeo, Raquel Bratos, Marcia S. Brose, Mark Messing, Lea Dutta, Corina E. Dutcus, Jie Huang, Emmett V. Schmidt, Robert Orlowski, Matthew H. Taylor

    Published 2023
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer

    TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer by Charles S. Fuchs, Marwan Fakih, Lee S. Schwartzberg, Allen Lee Cohn, Lorrin Yee, Luke Dreisbach, Mark Kozloff, Yong‐jiang Hei, Francesco Galimi, Yang Pan, Vincent Haddad, Cheng‐Pang Hsu, Antony Sabin, Leonard B. Saltz

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

    A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer by J. Randolph Hecht, Edith P. Mitchell, Tarek Chidiac, Carroll Scroggin, Christopher Hagenstad, David R. Spigel, John L. Marshall, Allen Lee Cohn, David McCollum, Philip J. Stella, Robert G Deeter, Seta Shahin, Rafael G. Amado

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines

    Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines by Heinz‐Josef Lenz, Eric Van Cutsem, Shirin Khambata‐Ford, Robert J. Mayer, Philip J. Gold, Philip J. Stella, B. Mirtsching, Allen Lee Cohn, Andrew W. Pippas, N. Azarnia, Zenta Tsuchihashi, David J. Mauro, Eric K. Rowinsky

    Published 2006
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer

    Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer by David R. Fogelman, Antonio Cubillo, Pilar García‐Alfonso, María Luisa Limón Mirón, John Nemunaitis, Daniel Flora, Christophe Borg, Laurent Mineur, J.M. Viéitez, Allen Lee Cohn, Gene Saylors, Albert Assad, Julie Switzky, Li Zhou, Johanna C. Bendell

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Axitinib and/or bevacizumab with modified FOLFOX‐6 as first‐line therapy for metastatic colorectal cancer: A randomized phase 2 study

    Axitinib and/or bevacizumab with modified FOLFOX‐6 as first‐line therapy for metastatic colorectal cancer: A randomized phase 2 study by Jeffrey R. Infante, Tony R. Reid, Allen Lee Cohn, William J. Edenfield, Terrence P. Cescon, John Hamm, Imtiaz A. Malik, Thomas A. Rado, Philip J. McGee, Donald Richards, Jamal Tarazi, Brad Rosbrook, Sinil Kim, Thomas H. Cartwright

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer

    A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer by Johanna C. Bendell, Howard S. Höchster, Lowell L. Hart, Irfan Firdaus, Joseph R. Mace, Joshua J. McFarlane, Mark Kozloff, Daniel V.T. Catenacci, Jessie J. Hsu, Stephen P. Hack, David S. Shames, See‐Chun Phan, Hartmut Koeppen, Allen Lee Cohn

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set

    Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set by Eric A. Klein, Donald Richards, Allen Lee Cohn, Meghna Tummala, Rosanna L. Lapham, David O. Cosgrove, Gina G. Chung, Jessica Clement, Jingjing Gao, Nathan Hunkapiller, Arash Jamshidi, Kathryn N. Kurtzman, Michael V. Seiden, Charles Swanton, M C Liu

    Published 2021
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146

    Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146 by Vicky Makker, Matthew H. Taylor, Carol Aghajanian, Allen Lee Cohn, Marcia S. Brose, Christopher Di Simone, Zhu Cao, Leah Suttner, Andrey Loboda, Rǎzvan Cristescu, Petar Jelinic, Robert Orlowski, Lea Dutta, Junji Matsui, Corina E. Dutcus, Yukinori Minoshima, Mark Messing

    Published 2024
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression

    Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metast... by Radka Obermannová, Eric Van Cutsem, Takayuki Yoshino, G. Bodoky, Jana Prausová, Rocio García‐Carbonero, Tudor‐Eliade Ciuleanu, Pilar Alfonso, David C. Portnoy, Allen Lee Cohn, Kentaro Yamazaki, P. Clingan, Sara Lonardi, Tae‐Woo Kim, Lifen Yang, Federico Nasroulah, Josep Tabernero

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

    Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase... by Harry H. Yoon, Johanna C. Bendell, Fadi S. Braiteh, Irfan Firdaus, P. A. Philip, Allen Lee Cohn, Nancy Lewis, D. Mark Anderson, Edward Arrowsmith, Jonathan D. Schwartz, Ling Gao, Yanzhi Hsu, Yiwen Xu, D. Ferry, Steven R. Alberts, Zev A. Wainberg

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study

    Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study by Eric Van Cutsem, C. Boni, Josep Tabernero, Bartomeu Massutí, Gary Middleton, Faysal Dane, Peter Reichardt, Francisco Pimentel, Allen Lee Cohn, Philippe Follana, Michael Clemens, Alberto Zaniboni, Vladimir Moiseyenko, Mark Harrison, Donald Richards, Hans Prenen, Simon Pernot, Evelyne Ecstein-Fraïsse, Simon Hitier, P. Rougier

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer

    A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer by Allen Lee Cohn, Josep Tabernero, Joan Maurel, Elżbieta Nowara, Javier Sastre, Benjamin Chuah, М. В. Копп, Dina Sakaeva, Edith P. Mitchell, S. Dubey, Samuel Suzuki, Y.J. Hei, Francesco Galimi, Ian McCaffery, Yang Pan, Robert D. Loberg, Susan Cottrell, Su Pin Choo

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer

    Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer by Mitesh J. Borad, Shantan Reddy, Nathan Bahary, Hope E. Uronis, Darren Sigal, Allen Lee Cohn, William R. Schelman, Joe Stephenson, E. Gabriela Chiorean, Peter J. Rosen, Brian Ulrich, Tomislav Dragovich, Salvatore A. Del Prete, Mark U. Rarick, Clarence Eng, Stew Kroll, David P. Ryan

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

    Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study by Josep Tabernero, Rebecca R. Hozak, Takayuki Yoshino, Allen Lee Cohn, Radka Obermannová, G. Bodoky, Rocio García‐Carbonero, Tudor‐Eliade Ciuleanu, David C. Portnoy, Jana Prausová, Kei Muro, Robert W. Siegel, Robert J. Konrad, Haojun Ouyang, Symantha Melemed, D. Ferry, Federico Nasroulah, Eric Van Cutsem

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

    Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer by Vicky Makker, Matthew H. Taylor, Carol Aghajanian, Ana Oaknin, James W. Mier, Allen Lee Cohn, Margarita Romeo, Raquel Bratos, Marcia S. Brose, Christopher DiSimone, Mark Messing, Daniel E. Stepan, Corina E. Dutcus, Jane Wu, Emmett V. Schmidt, Robert Orlowski, Perminder S. Sachdev, Robert Shumaker, Antonio Casado

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors

    A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors by Gayle Jameson, John Hamm, Glen J. Weiss, Carlos Alemany, Stephen P. Anthony, M. Basche, Ramesh K. Ramanathan, Mitesh J. Borad, Raoul Tibes, Allen Lee Cohn, Ioana Hinshaw, Robert M. Jotte, Lee S. Rosen, Ute Hoch, Michael A. Eldon, Robert A. Medve, Katrina Schroeder, Erica White, Daniel D. Von Hoff

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: